Is Forteo classified as a bisphosphonate?

• A. Yes
• B. No
• C. Only in high doses
• D. Only for fracture treatment

Answer: (B)

Forteo, known generically as teriparatide, is not classified as a bisphosphonate. Instead, it is a recombinant form of parathyroid hormone (PTH) that is used primarily to treat osteoporosis in patients at high risk for fracture. Bisphosphonates, on the other hand, are a class of drugs that primarily work by inhibiting osteoclast-mediated bone resorption, thereby increasing bone density.

The mechanism of action for Forteo is fundamentally different. By stimulating osteoblast activity, Forteo promotes bone formation, which is distinct from the action of bisphosphonates. This key difference in their effects on bone metabolism is important for understanding their applications in clinical practice. Forteo is particularly effective in individuals who have already experienced fractures or are at significant risk due to low bone density, which further differentiates it from bisphosphonates, which are often first-line treatments but don't promote bone formation to the same extent as Forteo.